NCT02966691 - Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors | Biotech Hunter

Enrollment

1,360

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

January 16, 2021

Conditions

Bladder Cancer

Interventions

OTHER

VisioCyt® diagnostic test

The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.

Trial Locations (14)

13009

Institut Paoli-Calmettes, Marseille

25000

CHU de Besançon, Besançon

30029

CHU Caremeau, Nimes, Nîmes

34070

Clinique BeauSoleil, Montpellier

35033

CHU Rennes, Rennes

44093

Hôtel Dieu, CHR de Nantes, Nantes

54500

CHRU Nancy, Vandœuvre-lès-Nancy

Unknown

Hôpital d'Antony, Antony

"Clinique la Châtaigneraie ", Beaumont

CHU de Clermont-Ferrand, Clermont-Ferrand

Hôpital Edouard Herriot, Lyon

Hôpital Cochin, Paris

Hôpital Foch, Suresnes

Hopital Rangueil, Toulouse

All Listed Sponsors

collaborator

FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

UNKNOWN

collaborator

SATT Paris Saclay

UNKNOWN

lead

Vitadx

OTHER